Navigation Links
Cytopia Lodges IND for JAK2 Inhibitor CYT387
Date:6/22/2009

MELBOURNE, Australia, June 22 /PRNewswire/ -- Cytopia Ltd (ASX: CYT) announced today that it has filed an Investigational New Drug Application (IND) with the US Food and Drug Administration (FDA) for its novel, potent orally active JAK2 inhibitor CYT387.

Following FDA review, the company intends to commence a Phase I/II trial for CYT387 in patients with myelofibrosis, a serious progressive and chronic condition where scar tissue develops in the bone marrow. CYT387 is expected to be the second Cytopia developed drug candidate in clinical studies and the first trialled in the United States, with the anticancer

vascular disrupting agent CYT997 now in Phase II clinical studies in Australia.

Over-activity of the JAK2 enzyme is implicated in a variety of haematological conditions known as the myeloproliferative disorders (MPDs). This suite of conditions includes myelofibrosis, polycythemia vera and essential thrombocythemia. Cytopia has demonstrated that CYT387 inhibits the overactive JAK2 enzyme in an invivo preclinical model and in cells from patients with MPDs. This data suggests that the compound may exert a profound effect on the human disease.

Myelofibrosis results in a compromised ability of patients to produce sufficient blood cells and a reliance on organs other than the bone marrow, including the liver and spleen, to produce cells. Typical symptoms include an enlarged spleen and progressive anemia and poor overall survival.

"The filing of an IND for CYT387 is the culmination of a comprehensive preclinical development effort by the Cytopia Drug Development team," said Mr Andrew Macdonald, CEO of Cytopia. "Our deep knowledge of the JAK2 target has been integral to the design of this drug and the program is significantly bolstered by the intellectual property we hold over the JAK2 target."

The clinical utility of CYT387 is also expected to have broader applicability in diseases driven by disregulated JAK2 signalling, including some cancers and various inflammatory conditions. Cytopia is

exploring the utility of CYT387 in these conditions.

About Cytopia

Cytopia Ltd is an Australian biotechnology company focused on the development of new drugs to treat cancer and other diseases. Cytopia conducts its drug development through subsidiaries based in Australia

and USA and specializes in developing new small molecule compounds with an improved therapeutic profile for the treatment of cancer.

The lead program for the company is CYT997, a vascular disrupting agent (VDA) for the treatment of various cancers, currently being trialed in Phase II clinical studies. This compound is delivered orally as well as intravenously. Cytopia also has built on its range of JAK and other kinase inhibitors with CYT387, a novel oral JAK2 inhibitor focused on the treatment of myeloproliferative disorders and cancer, expected to enter Phase I clinical studies in 2009.


'/>"/>
SOURCE Cytopia Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cytopia To Present Data on FMS Program With Anticancer Potential
2. Cytopia Commences Phase II Cancer Drug Study
3. Potent metastasis inhibitor identified
4. Small molecule inhibitor shows promise in trastuzumab-resistant metastatic breast cancer
5. Cylene to Announce New Data on Its First-in-Class Oral CK2 Inhibitor Against Cancer at BIO Conference
6. For the Treatment of Rheumatoid Arthritis, Market Share for TNF-alpha Inhibitors Will Decrease Through 2018
7. Video: Novartis Receives Approval From FDA to Market Prevacid(R) 24HR as First and Only OTC Proton Pump Inhibitor in Original Prescription Formulation
8. SCAI Statement on A National Study of the Effect of Individual Proton Pump Inhibitors on Cardiovascular Outcomes in Patients Treated with Clopidogrel Following Coronary Stenting: The Clopidogrel Medco Outcomes Study
9. Alseres and BioAxone Amend License Agreement for Cethrin(R) and Rho Inhibitor Technology
10. Potential lung disease biomarkers yield clues to COX-2 inhibitor side effects
11. Experimental insulin-like growth factor receptor inhibitor reduced pancreatic cancer growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... 2016 , ... CarriersEdge, providers of online safety and compliance training tools for ... Offered in three modules, the courses can be used as an extension to an ... how to stay healthy on the road. , “CarriersEdge is now offering a way ...
(Date:12/6/2016)... ... 06, 2016 , ... Of the variety of ingredients in the food supply, ... contrary to common beliefs that hot dogs include “everything but the oink,” today’s wieners ... Ingredients combined with meat and poultry in a hot dog recipe can add flavor, ...
(Date:12/6/2016)... ... December 06, 2016 , ... The NALA, a boutique marketing agency, is ... Foundation (TBCF), a nonprofit 501(C)(3) organization providing financial and emotional support to families ... To assist TBCF, the NALA recently hosted a Thanksgiving food drive that resulted in ...
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... ... Autism Center with an Award of Distinction, recognizing the organization as a top ... that excel in the areas of clinical quality, staff satisfaction and qualifications, and ...
(Date:12/6/2016)... Yorba Linda, Ca (PRWEB) , ... December 06, ... ... one of the fastest growing fields in research and development, largely due to ... investigated, including human mesenchymal stem cells (hMSCs) and human induced pluripotent stem cells ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... , Dec. 5, 2016   Mallinckrodt Pharmaceuticals ... pharmaceutical company, today announced that it received a perfect ... Index (CEI), a national benchmarking survey and report on ... and transgender (LGBT) workplace equality, administered by the Human ... 517 major U.S. businesses which also earned top marks ...
(Date:12/5/2016)... 5, 2016  Cornerstone Pharmaceuticals, Inc., a privately ... from two Phase I trials evaluating its lead ... annual meeting of the American Society of Hematology ... . The two datasets show encouraging efficacy and ... (AML) and T-cell non-Hodgkin,s lymphoma (T-cell NHL), respectively, ...
(Date:12/5/2016)... BOULDER, Colo. , Nov. 29, 2016 ... webinar hosted by Accera, Inc. at 11 ... 9th Annual International Conference on Clinical Trials for Alzheimer,s ... role of metabolism in Alzheimer,s disease and therapeutic targets ... patients. "Following the recent failure of another ...
Breaking Medicine Technology: